Drug Profile


Alternative Names: AP 1007; AP 1431; AP 1450; AP 1451; ISIS 2302

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Atlantic Healthcare
  • Class Anti-inflammatories; Antipsoriatics; Antisense oligonucleotides; Thionucleotides
  • Mechanism of Action Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pouchitis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease; Pouchitis; Ulcerative colitis

Highest Development Phases

  • Preregistration Pouchitis
  • Phase III Ulcerative colitis
  • Preclinical Crohn's disease
  • Discontinued Asthma; Inflammation; Psoriasis; Renal transplant rejection; Rheumatoid arthritis

Most Recent Events

  • 18 Sep 2017 Atlantic Pharmaceuticals initiates enrolment a phase III trial in France, Italy, Ireland, Netherlands, and United Kingdom after December 2015 (NCT02525523)
  • 12 Jun 2017 Alicaforsen tablet is available for licensing in Canada, Japan, World (excluding USA, Europe) as of 12 Jun 2017.
  • 12 Jun 2017 Preclinical trials in Crohn's disease in Japan, USA, Canada, Europe (PO) (Atlantic Healthcare pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top